Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5713380 | 0.88 | ALDH1A1 (0.48) | HTTSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL26757977 | 0.87 | HTT (0.56) | HTTPOLBSMN1; SMN2TMEM97SIGMAR1 | |
| SCHEMBL7460757 | 0.85 | CYP1A2 (0.64) | HTTPOLBSMN1; SMN2CYP1A2MAPT | |
| SCHEMBL7237555 | 0.84 | MAPT (0.54) | POLBSMN1; SMN2MAPTALDH1A1MEN1 | |
| SCHEMBL18770223 | 0.84 | HTT (0.53) | HTTPOLBSMN1; SMN2TMEM97SIGMAR1 | |
| SCHEMBL31203036 | 0.83 | HTT (0.67) | HTTPOLBSMN1; SMN2TMEM97SIGMAR1 | |
| SCHEMBL7463468 | 0.81 | ALDH1A1 (0.55) | HTTPOLBSMN1; SMN2TMEM97SIGMAR1 | |
| SCHEMBL6111089 | 0.80 | MCHR1 (0.53) | HTTPOLBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7476700 | 0.80 | HTT (0.49) | HTTPOLBSMN1; SMN2TMEM97SIGMAR1 | |
| SCHEMBL20567883 | 0.79 | ALDH1A1 (0.53) | HTTPOLBSMN1; SMN2TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973727-B8 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA INTERNATIONAL INC (BB) | 2006-01-18 | — | — | EP | disclosed |
| EP-0973727-B1 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA INC (CA) | 2005-10-26 | — | — | EP | disclosed |
| US-6780995-B2 | VIRICIDES; ANTICANCER AGENTS | ISOTECHNIKA INC. (CA) | 2004-08-24 | — | — | US | disclosed |
| US-20030187015-A1 | Activated iododerivatives for the treatment of cancer and aids | YATSCOFF RANDALL W (CA) | 2003-10-02 | — | — | US | disclosed |
| US-6511988-B2 | Prevention binding of transcription factor tozinc finger binding compounds | ISOTECHNIKA INC. (CA) | 2003-01-28 | — | — | US | disclosed |
| US-20020019538-A1 | Activated iododerivatives for the treatment of cancer and aids | ISOTECHNIKA INC. (CA) | 2002-02-14 | — | — | US | disclosed |
| US-6306871-B1 | IODONITROBENZAMIDE DERIVATIVES AS ANTICARCINOGENIC, ANTITUMOR AGENTS AND VIRICIDES | ISOTECHNIKA INC. (CA) | 2001-10-23 | — | — | US | disclosed |
| US-6225323-B1 | Activated iododerivatives for the treatment of cancer and AIDS | JOSEPH KOZIAK (CA) | 2001-05-01 | — | — | US | disclosed |
| EP-0973727-A2 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA,INC. (CA) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998045253-A1 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA, INC. (CA) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019538-A1 | Activated iododerivatives for the treatment of cancer and aids | IKZF3, ZC3HAV1, ZFP3 | HTT 4176/4885POLB 656/4885SMN1; SMN2 4497/4885 |
| US-20030187015-A1 | Activated iododerivatives for the treatment of cancer and aids | IKZF3, ZC3HAV1, ZFP3 | HTT 4176/4885POLB 656/4885SMN1; SMN2 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.